title: Impact of HPV16/18 vaccination on quality of life: a pilot study.
abstract: OBJECTIVE
  Genital human papillomavirus (HPV) infections and associated precancerous lesions adversely affect health-related quality of life (HRQoL). HPV vaccines provide effective protection against these conditions. We therefore investigated the impact of HPV vaccination on HRQoL in young women five years after participation in a phase III HPV vaccination trial.
  
  
  METHODS
  A total of 4808 originally 16- to 17-year-old Finnish girls had participated in the PATRICIA trial and received either bivalent HPV 16/18 vaccine or hepatitis A-virus (HAV) vaccine in 2004 to 2005. Unvaccinated girls (n = 9602), from adjacent birth cohorts, had participated in the control cohort in 2005. From 2009 to 2011, at 22 to 23 years of age, all participants received a questionnaire consisting of two generic HRQoL instruments (RAND36 and EQ VAS) and a disease-specific questionnaire (CECA10).
  
  
  RESULTS
  We analysed responses of 1143 HPV 16/18-vaccinated, 980 HAV-vaccinated, and 3753 unvaccinated young women. The unadjusted mean outcome measures of the different HRQoL estimates were similar in the three different responder cohorts.
  
  
  CONCLUSIONS
  Five years after vaccination the health-related quality of life of HPV 16/ 18- vaccinated young women did not differ from those of HAV-vaccinated or unvaccinated controls representing the general population.
authors.affiliation: * School of Health Sciences, University of Tampere , Tampere , Finland.
authors.forename: Tiina
authors.initials: T
authors.lastname: Eriksson
authors.forename: Saku
authors.initials: S
authors.lastname: Torvinen
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Woodhall
authors.forename: Mirjami
authors.initials: M
authors.lastname: Lehtinen
authors.forename: Dan
authors.initials: D
authors.lastname: Apter
authors.forename: Katja
authors.initials: K
authors.lastname: Harjula
authors.forename: Mari
authors.initials: M
authors.lastname: Hokkanen
authors.forename: Pekka
authors.initials: P
authors.lastname: Rissanen
authors.forename: Jorma
authors.initials: J
authors.lastname: Paavonen
authors.forename: Matti
authors.initials: M
authors.lastname: Lehtinen
mesh_terms: D000293:Adolescent; D000328:Adult; D003218:Condylomata Acuminata / Q000517:prevention & control; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006506:Hepatitis A / Q000517:prevention & control; D022362:Hepatitis A Vaccines; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D010865:Pilot Projects; D011788:Quality of Life / Q000523:psychology*; D012725:Sexual Behavior; D011795:Surveys and Questionnaires; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control; D014611:Vaccination / Q000523:psychology*; D055815:Young Adult
chemical_list: D022362:Hepatitis A Vaccines; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18